MRMD earnings analysis
What we found in MRMD's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
The provided 10-Q excerpt is limited to controls, legal proceedings, risk factors, and exhibits and does not include the income statement, balance sheet, cash flow statement, or segment disclosures. Controls were deemed effective as of June 30, 2026, with no material changes to internal control during the quarter. The filing reports no material changes to the risk factors from the December 31, 2025 Annual Report, while documenting $8,000,000 of promissory-note principal.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Effective Disclosure Controls
- Management concluded that disclosure controls were effective as of June 30, 2026, supporting the timeliness and reliability of reported information.
- No Material Control Changes
- The filing reports no change during the fiscal quarter ended June 30, 2026 that materially affected, or was reasonably likely to materially affect, internal control over financial reporting.
- Financing Arrangements Disclosed
- The filing identifies two February 24, 2026 promissory notes with principal amounts of $2,000,000 and $6,000,000, documenting the company’s current financing arrangements.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Debt and Refinancing Exposure
- The company has promissory notes totaling $8,000,000 in stated principal—$2,000,000 and $6,000,000—issued on February 24, 2026, creating debt-servicing and refinancing exposure.
- Regulatory and Litigation Risk
- MariMed states that the cannabis industry is highly regulated and that compliance issues can lead to regulatory investigations, litigation, or disciplinary action; the filing also notes increasing cannabis-industry class-action litigation in past years.
- Employment Claims
- The company faces claims from former employees alleging wrongful termination and similar conduct. Although management states these claims are not material, the filing says such claims arise from time to time in the ordinary course.
What they said about what is next.
The provided 10-Q excerpt contains no quantitative revenue or EPS guidance. Management states that there were no material changes to the risk factors in the Annual Report for the year ended December 31, 2025.
The filing reads about the same as the one before it.
What came before.
- 10-Q · May 14, 2026
- MariMed reported Q1 2026 results with a revenue of $39.5 million, surpassing estimates of $38.25 million, while maintaining an EPS loss of $0.01 in line with expectations. The company's net loss improved to $3.8 million…
- 10-K · March 12, 2026
- MariMed grew revenue modestly to $159.826M in 2025 (up 1.3% YoY) while generating positive operating cash flow of $7.695M and free cash flow of ~$6.528M. Wholesale expansion (wholesale revenue $69.579M, +10.6%) and…
- 10-Q · November 6, 2025
- MariMed reported essentially flat revenue of $40.76M in Q3 2025 (vs $40.60M in Q3 2024) while gross profit slipped and tax expense surged, producing a larger net loss. Operating income improved modestly to $1.599M, but…
- 10-Q · August 7, 2025
- MariMed reported Q2 revenue of $39,611,000 (down $827,000 or 2.0% YoY from $40,438,000) but up sequentially $1,656,000 (4.4%) from Q1's $37,955,000. Gross margin was 40.5% in Q2 and operating income improved to…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing MRMD makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever